dtp3

DTP3 is a selective MKK7/GADD45β inhibitor, which inhibits cancer-selective NF-κB survival pathway.

DTP3 TFA (1809784-29-9 free base) (DTP3 TFA) is a potent and selective GADD45β/MKK7 (growth arrest and DNA-damage-inducible β/mitogen-activated protein kinase kinase 7) inhibitor.

DTP348 is an oral dual CAIX inhibitor/ radiosensitizer. DTP 348 is an oral dual drug with two mechanisms of action: (1). carbonic anhydrase IX inhibitor which acidifies the intracellular pH through the sulfamide components; (2). radio sensitizer of hypoxic cells through its 5-nitroimidazole moiety.

CRV431 is a novel Pan-Cyclophilin Inhibitor, potently inhibiting all cyclophilin isoforms tested - A, B, D, and G (IC50 values ranged from 1-7 nM).

LLLEVPGS TFA is a peptide widely used in biochemical experiments and drug synthesis research.

SP 600125, negative control is a methylated analog of SP 600125 and can be used as a negative control for SP 600125. SP 600125, negative control inhibits DTP3 and GADD45β/MKK7 (growth arrest and DNA damage-inducible β/mediator-activated protein kinase kinase kinase 7) and is capable of restoring activation.The IC50s of SP 600125, negative control against JNK2 and JNK3 were 18 and 24 μM, respectively.